Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks
mechanism

G-actin sequestration

also: actin sequestration, G-actin buffering, thymosin beta-4 actin sequestration

The binding and buffering of monomeric globular actin (G-actin) by sequestering proteins, regulating the cytoplasmic pool available for actin filament polymerization and cell motility.

G-actin sequestration refers to the reversible binding of monomeric globular actin (G-actin) by intracellular sequestering proteins, most prominently members of the thymosin beta family. This binding keeps G-actin in a soluble, polymerization-competent but non-filamentous state, creating a dynamic buffer that controls the free G-actin concentration available to drive barbed-end polymerization of F-actin (filamentous actin) and thus regulates the rate and directionality of cytoskeletal reorganization.

Why it matters in peptide research

Actin dynamics are fundamental to cell migration, wound healing, immune cell function, and tissue remodeling. During wound repair, keratinocytes, fibroblasts, endothelial cells, and immune cells must rapidly migrate from wound margins into the injury zone — a process requiring precisely coordinated cycles of actin polymerization at the leading edge and depolymerization at the trailing edge. The availability of the G-actin pool can limit the rate of this migration.

Thymosin beta-4 (Tβ4), a major G-actin-sequestering peptide in mammalian cells, normally keeps actin in a sequestered, reserve state. Upon cell activation by chemotactic signals, thymosin beta-4 releases G-actin to profilin and actin nucleators (Arp2/3, formins) that direct filament growth at the membrane. This regulated release is what allows cells to rapidly extend lamellipodia and filopodia toward repair signals.

Whether thymosin beta-4 given from outside the cell adds to this buffer is a hypothesis. In laboratory studies full-length thymosin beta-4 is also reported to affect inflammatory cytokine expression, cardiomyocyte survival and VEGF expression. TB-500 is not the full-length peptide: it is a synthetic seven-amino-acid fragment (Ac-LKKTETQ), and the cardiac, eye and wound-healing work usually quoted for it is mostly on the full protein. In a 2024 analysis of TB-500 and its metabolites, only the metabolite Ac-LKKTE showed significant wound-healing activity against control, in experiments on fibroblasts (connective-tissue cells grown in the laboratory).

Peptides that act on this

  • TB-500 (synthetic thymosin beta-4 fragment, Ac-LKKTETQ) — the name used for a product sold as a fragment of thymosin beta-4; whether it sequesters G-actin as the full protein does is not shown. Its page gives what has been studied, the PubMed search for human trials and FDA's full entry. FDA's page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (content current as of 22 April 2026) says: "Compounded drugs containing thymosin Beta-4, Fragment (LKKTETQ) may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation as well as peptide-related impurities."
  • Thymosin Beta-4 — full-length endogenous 43-amino-acid peptide; TB-500 is a seven-amino-acid fragment of it.

Common misconceptions

G-actin sequestration by thymosin beta-4 is sometimes described as "blocking" actin polymerization — a mischaracterization that frames the sequestered pool as inert. In reality, sequestered G-actin is a charged, ready reservoir: the sequestration is dynamically regulated and instantly reversible upon cellular activation, making it a storage mechanism for rapid-response cytoskeletal remodeling rather than a static inhibitory state. Whether TB-500 acts through this mechanism has not been shown.

Published: 2026-05-16Last updated: 2026-11-06
  • Correction (2026-11-06): Corrected 6 November 2026 after a dose and citation audit: the claim that TB-500 acts as thymosin beta-4 does was removed, since TB-500 is a fragment and most of the work quoted for it is on the full protein; an unsourced concentration estimate was removed; FDA's TB-500 safety statement was added.

If you spot an error or have new evidence to suggest, please use our corrections policy.

Related glossary entries